The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Moving Forward With Results From CheckMate-142 in MSI-H mCRC

Thierry Andre, MD
Published Online:7:36 PM, Mon July 9, 2018

Thierry Andre, MD, professor of medical oncology at the University Pierre et Marie Curie (UMPC) and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux in Paris, discusses the introduction of immunotherapy to the treatment landscape of metastatic colorectal cancer (mCRC). 

In CheckMate-142, an immunotherapy combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) was tested in a small subset of patients with mCRC. According to Andre, the study looked at patients with 
microsatellite instability-highmCRC with a primary objective of overall response. There was a 55% response rate in this patient population, with the combination demonstrating a low toxicity profile that was only slightly higher than what is found with monotherapy. Also, toxicity-related discontinuation occurred in just a small number of patients, around 15%. 

Andre notes this trial was not randomized and the combination was only tested in a small population of patients. This particular subset of patients only makes up about 4% of the CRC population. However, Andre says this is only the beginning of immunotherapy in this setting. 

Andre notes that we have already seen the results for nivolumab, pembrolizumab (Keytruda), and now this combination. In the future, trials must recruit larger patient populations in CRC, by looking at CMS classification, mutations, or other characteristics. 
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.